🔍 What does the recent decision by the German Federal Joint Committee mean for patients with urothelial carcinoma?
The approval of Pembrolizumab Enfortumab therapy as a first-line treatment opens new avenues for patient care, particularly for those eligible for cisplatin-based regimens. However, the economic implications of its high costs and selective effectiveness raise pressing questions about healthcare accessibility.
Curious about the balance between clinical benefits and economic realities in cancer treatment? Click to explore the full article!
#SyenzaNews #HealthEconomics #oncology #MarketAccess